ArTara is an abbreviation of the name Arya Tara, given to the only female form of the Buddha. Arya Tara represents the virtues of health, healing and compassion.
We believe Arya Tara reflects our personal and corporate aspirations to fully support patients with rare diseases. Additionally, Arya Tara represents our view that only by reflecting the diversity that characterizes our world can we truly understand and treat rare diseases which often know no boundaries of age, gender, race, religion or socioeconomic background.
TARA 002 for the treatment of Lymphatic Malformations (LMs)
Our lead program is TARA 002, an investigational cellular therapy based on OK-432, an immunostimulant currently approved in Japan and Taiwan, that has been standard of care in LMs for over 20 years. Lymphatic malformations are rare, non-malignant masses that primarily form in the head and neck region of children before the age of two. Radiographically, lymphatic malformations have been categorized into three subtypes – macrocystic, microcystic, or mixed (a combination of the other two). In the US and Europe, the standard of care is surgical excision, which is associated with high rates of recurrence and complications.1 A US-based, multicenter study in more than 600 patients, led by the University of Iowa, demonstrated that OK-432, was safe and effective in the treatment of macrocystic and mixed LMs.
OK-432 has been granted orphan drug designation by the FDA.
1Perkins, J. et al. Otolaryngology–Head and Neck Surgery. 2010; 142(6):795-803